Search results for "biodistribution"

showing 4 items of 94 documents

Biodistribution and post-therapy dosimetric analysis of [177Lu]Lu-DOTAZOL in patients with osteoblastic metastases: first results

2019

Abstract Background Preclinical biodistribution and dosimetric analysis of [177Lu]Lu-DOTAZOL suggest the bisphosphonate zoledronate as a promising new radiopharmaceutical for therapy of bone metastases. We evaluated biodistribution and normal organ absorbed doses resulting from therapeutic doses of [177Lu]Lu-DOTAZOL in patients with metastatic skeletal disease. Method Four patients with metastatic skeletal disease (age range, 64–83 years) secondary to metastatic castration-resistant prostate carcinoma or bronchial carcinoma were treated with a mean dose of 5968 ± 64 MBq (161.3 mCi) of [177Lu]Lu-DOTAZOL. Biodistribution was assessed with serial planar whole body scintigraphy at 20 min and 3,…

lcsh:Medical physics. Medical radiology. Nuclear medicine[177Lu]Lu-DOTAZOLBiodistributionKidneyUrinary bladderbusiness.industrymedicine.medical_treatmentlcsh:R895-920Organ absorbed dosesBone metastasisBisphosphonatemedicine.diseaseProstate carcinomamedicine.anatomical_structureAbsorbed doseRadionuclide therapymedicineRadiology Nuclear Medicine and imagingBone marrowBronchial carcinomabusinessNuclear medicineBone seeking therapeutic radionuclidesOriginal ResearchEJNMMI Research
researchProduct

Labeling of DOTA-conjugated HPMA-based polymers with trivalent metallic radionuclides for molecular imaging.

2017

Background In this work, the in vitro and in vivo stabilities and the pharmacology of HPMA-made homopolymers were studied by means of radiometal-labeled derivatives. Aiming to identify the fewer amount and the optimal DOTA-linker structure that provides quantitative labeling yields, diverse DOTA-linker systems were conjugated in different amounts to HPMA homopolymers to coordinate trivalent radiometals Me(III)* = gallium-68, scandium-44, and lutetium-177. Results Short linkers and as low as 1.6% DOTA were enough to obtain labeling yields > 90%. Alkoxy linkers generally exhibited lower labeling yields than alkane analogues despite of similar chain length and DOTA incorporation rate. High sta…

lcsh:Medical physics. Medical radiology. Nuclear medicinelcsh:R895-920Gallium-68610 MedizinDOTA-HPMA conjugatesPETBiodistributionTheranostic610 Medical sciencesScandium-44Lutetium-177neoplasmsOriginal ResearchRadiolabelingEJNMMI research
researchProduct

Targeting CD34+ cells of the inflamed synovial endothelium by guided nanoparticles for the treatment of rheumatoid arthritis

2019

Abstract Despite the advances in the treatment of rheumatoid arthritis (RA) achieved in the last few years, several patients are diagnosed late, do not respond to or have to stop therapy because of inefficacy and/or toxicity, leaving still a huge unmet need. Tissue-specific strategies have the potential to address some of these issues. The aim of the study is the development of a safe nanotechnology approach for tissue-specific delivery of drugs and diagnostic probes. CD34 + endothelial precursors were addressed in inflamed synovium using targeted biodegradable nanoparticles (tBNPs). These nanostructures were made of poly-lactic acid, poly-caprolactone, and PEG and then coated with a synovi…

musculoskeletal diseases0301 basic medicineBiodistributionCD34; +; cells; Neoangiogenesis; Rheumatoid arthritis; Targeted nanoparticles; Targeted therapymedicine.medical_treatmentTargeted nanoparticlesImmunologyArthritisInflammation+Targeted therapyTargeted therapy03 medical and health sciences0302 clinical medicinemedicineImmunology and AllergyProgenitor cellRheumatoid arthritisRheumatoid arthritiTargeted nanoparticleNeoangiogenesis030203 arthritis & rheumatologybusiness.industrycellmedicine.diseaseNeoangiogenesi030104 developmental biologyRheumatoid arthritisToxicityCancer researchcellsMethotrexateCD34medicine.symptombusinessmedicine.drug
researchProduct

Realization of polyaspartamide-based nanoparticles and in vivo lung biodistribution evaluation of a loaded gucocorticoid after aerosolization in mice

2016

Abstract In this study, novel polymeric nanoparticles (NPs) were developed and their potential as carriers for beclomethasone dipropionate (BDP) into the lung after aerosolization was demonstrated by in vivo studies in mice. In particular, these NPs were obtained starting from two polyaspartamide-based copolymers which were synthesized by chemical reaction of α,β-poly(N-2-hydroxyethyl)- dl -aspartamide (PHEA) and its pegylated derivative (PHEA-PEG2000) with poly(lactic acid) (PLA). To obtain nanosized particles, the high pressure homogenization (HPH)—solvent evaporation method was followed by using an organic phase containing both PHEA-PLA and PHEA-PEG2000-PLA (at a weight ratio equal to 1:…

polymeric nanoparticles beclomethasone dipropionate aerosolization in miceBiodistributionDrug Evaluation PreclinicalPolymeric nanoparticles Beclomethasone dipropionate (BDP) PolyhydroxyethylaspartamidePharmaceutical ScienceNanotechnology02 engineering and technology010402 general chemistry01 natural scienceschemistry.chemical_compoundMicePulmonary surfactantIn vivoPEG ratioAdministration InhalationmedicineAnimalsTissue DistributionGlucocorticoidsLungAerosolizationAerosolsChromatographyLungmedicine.diagnostic_testtechnology industry and agricultureBeclomethasonerespiratory system021001 nanoscience & nanotechnology0104 chemical sciencesLactic acidBronchoalveolar lavagemedicine.anatomical_structurechemistryNanoparticles0210 nano-technologyPeptidesBronchoalveolar Lavage Fluid
researchProduct